Home
Random
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
D. Western Therapeutics Institute, Inc.
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary<ref>Source: Yahoo Finance.</ref> == D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on developing drugs to serve patients worldwide. The company offers GLANATEC, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM staining and peeling. It is also developing H-1337, a multikinase inhibitor that has completed Phase I/IIa clinical trials for the treatment of glaucoma/ocular hypertension; K-134, an antiplatelet agent, which has completed Phase IIb trials to treat arteriosclerosis obliterans; DW-1001, an ophthalmic treatment agent in nonclinical studies; and DW-5LBT, a lidocaine patch for neuropathic pain after shingles. The company was founded in 1999 and is headquartered in Nagoya, Japan. == References and notes == [[Category:Thesis]] __INDEX__
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
